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The abilities of chemokines in orchestrating cellular migration are utilised by different (patho-)biological networks including
malignancies. However, except for CXCR4/CXCL12, little is known about the relation between tumour-related chemokine
expression and the development and progression of solid tumours like breast cancer. In this study, microarray analyses revealed the
overexpression of chemokine CXCL13 in breast cancer specimens. This finding was confirmed by real-time polymerase chain
reaction in a larger set of samples (n¼34) and cell lines, and was validated on the protein level performing Western blot, ELISA, and
immunohistochemistry. Levels of CXCR5, the receptor for CXCL13, were low in malignant and healthy breast tissues, and surface
expression was not detected in vitro. However, we observed a strong (P¼0.0004) correlation between the expressions of CXCL13
and CXCR5 in breast cancer tissues, indicating a biologically relevant role of CXCR5 in vivo. Finally, we detected significantly elevated
serum concentrations of CXCL13 in patients with metastatic disease (n¼54) as compared with controls (n¼44) and disease-free
patients (n¼48). In conclusion, CXCL13 is overexpressed within breast cancer tissues, and increased serum levels of this cytokine
can be found in breast cancer patients with metastatic disease pointing to a role of CXCL13 in the progression of breast cancer,
suggesting that CXCL13 might serve as a useful therapeutic target and/or diagnostic marker in this malignancy.
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Originally, chemokines (‘chemotactic cytokines’) and their recep-
tors gained substantial scientific interest because of their central
role in orchestrating immune responses by directing lymphocyte
movement to the thymus, lymphoid tissues, and sites of
inflammation (Luster, 1998). Recent evidence, however, has shown
that the unique abilities of chemokines in regulating cellular
migration are utilised by a much wider variety of (patho-)
biological networks, including developing haematological malig-
nancies and solid tumours (Balkwill, 2004).
The more than 40 human chemokines described are divided into
four groups as follows (Bacon et al, 2002): the ‘CXC’ chemokines,
defined by the presence of a single amino acid residue surrounded
by two cysteines; the ‘CC’ chemokines, defined by two adjoined
cysteine molecules; the ‘XC’ chemokines, defined by the loss of one
cysteine residue; and the ‘C3XC’ chemokines (three interposed
amino acids). Chemokines and their receptors are described by
their family (e.g., CXC) combined with the letter R or L (‘receptor’
and ‘ligand’) and a member-specific number.
Although it was self-evident that proteins guiding lymphocyte
migration and formation should be involved in the development
of haematological malignancies – as has been demonstrated for
T- and B-cell lymphomas (Fujii et al, 2002; Basso et al, 2004; Ek
et al, 2006; Harasawa et al, 2006), multiple myeloma (Alsayed et al,
2007), and leukaemias (Voermans et al, 2002; Chunsong et al,
2006) – reports about the role of chemokines and their receptors
in solid cancers have emerged only recently. For example, the
expression of CXCR4 on melanoma cells was associated with
increased rates of metastasis and patient mortality (Longo-Imedio
et al, 2005), whereas another study suggests that interleukin-8
(IL-8) and its two chemokine receptors CXCR1 and CXCR2 might
promote prostate cancer progression through autocrine signalling
of prostate cancer cells (Murphy et al, 2005). Other authors found
that CXCL12 might stimulate cell migration, cell growth, and
invasion of ovarian cancer cells (Scotton et al, 2002), and that
CXCR4 was found to be expressed on the majority of glioma cell
lines studied and on patients’ tissue samples. After adding the
CXCR4 agonist CXCL12, glioma cell lines were prevented from Received 2 June 2008; revised 30 July 2008; accepted 30 July 2008
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sapoptosis and showed increased chemotaxis (Zhou et al, 2002). A
role of the chemokine/receptor pair CXCL12/CXCR4, normally
controlling cell trafficking within the marrow (Nagasawa, 2000),
in the development of solid tumour bone marrow metastases
has been shown for small-cell lung cancer (Burger et al, 2003),
breast cancer (Muller et al, 2001), and renal cell cancer (Zagzag
et al, 2005). Accordingly, an entanglement of chemokine signalling
pathways with tumour cell properties, such as proliferation,
survival, adhesion, and chemotaxis, has been suggested (Laurence,
2006).
To gain insight into mechanisms by which chemokines might
affect breast cancer development through local and microenviro-
mental migration signalling, we analysed malignant and normal
tissue samples from patients with breast cancer regarding their
chemokine expression profiles.
CXCL13 is a chemokine ligand originally termed B-cell-
attracting chemokine 1 (bca-1), which is known to be
expressed by stromal cells within B-cell follicles in secondary
lymphoid tissues (Gunn et al, 1998). It has a crucial function
in germinal centre formation (Allen et al, 2004) through
interaction with its receptor CXCR5 expressed on follicular B
cells (Bowman et al, 2000). Under normal conditions, CXCL13 is
furthermore expressed by follicular dendritic cells (Vissers et al,
2001), macrophages (Carlsen et al, 2004), and germinal centre
T cells.
We found that CXCL13 is overexpressed within breast
cancer tissues at the mRNA and protein levels and that increased
serum levels of this cytokine can be found in breast cancer
patients with metastatic disease pointing to a possible role of
CXCL13 within the development and progression of breast
cancer.
MATERIALS AND METHODS
Patients, healthy blood donors, and breast cancer cell lines
A total number of 136 consecutive, consenting breast cancer
patients were included in the study. Operable patients (n¼34)
were admitted to the Mammazentrum at the Jerusalem Hospital in
Hamburg (Germany), and tumour samples as well as normal
adjacent tissues were collected during surgery. Non-malignant
tonsils were collected from consenting patients during routine
tonsillectomy performed at the Department of Otorhinolaryn-
gology at the University Medical Center Hamburg-Eppendorf
(Germany). Tissues were stored in RNAlater (Ambion, Austin, TX,
USA) at  801C until further use. Serum samples were obtained
from breast cancer patients receiving adjuvant treatment or
chemotherapy for metastasised disease at the Department of
Oncology/Hematology at the University Medical Center Hamburg-
Eppendorf. Serum samples from 44 blood donors were obtained as
controls. The study protocol had received approval by the local
ethics committee.
Breast cancer cell lines and short-term-activating culture
Human breast cancer cell lines, MDA-MB-231, MDA-MB-453,
MDA-MB-468, MCF-7, ZR-75, BT-20, and CAMA-1, were kindly
provided by the New York branch of the Ludwig Institute for
Cancer Research. Cell lines were maintained in DMEM supple-
mented with 10% foetal bovine serum, 100Uml
 1 penicillin and
streptomycin (Invitrogen, Carlsbad, CA, USA). For cytokine-
induced activation, cell lines were cultured for 72h in complete
medium with or without activating cytokines TNF-a (25ngml
 1;
BD Bioscience, San Jose, CA, USA), INF-g (100Uml
 1;R & D
Systems, Minneapolis, MN), or both. Cells were harvested and were
analysed for the expressions of CXCL13 and CXCR5 at baseline as
well as after 24, 48, and 72h.
Reverse-transcription PCR
Total RNA was extracted from cell lines applying the RNeasy Mini
Kit (Qiagen, Hilden, Germany) and from tissue samples using
guanidium isothiocyanate for denaturation, followed by caesium
chloride gradient ultracentrifugation overnight (36000r.p.m.,
41C). Reverse transcription was performed using AMV reverse
transcriptase (Promega, Madison, WI, USA) and was run at
421C for 45min with heat inactivation of the enzyme at 951C
for 5min. Polymerase chain reaction primers and conditions
used for the analysis are as follows: CXCL13 forward primer (F):
50-GAGGCAGATGGAACTTGAGC-30; CXCL13 reverse primer (R):
50-CTGGGGATCTTCGAATGCTA-30;C X C R 5 - F :5 0-CTTCGCCAAAGT
CAGCCAAG-30;C X C R 5 - R :5 0-TGGTAGAGGAATCGGGAGGT-30;
GADPH-F: 50-TGATGACATCAAGAAGGTGG-30; and GADPH-R:
50-TTTCTTACTCCTTGGAGGCC-30. For PCR analysis of single
genes, 4ml first-strand cDNA (equivalent to 0.1mg RNA) was
amplified after the preparation of 25ml of PCR reaction mixtures
containing transcript-specific oligonucleotides (10pM), 2U of
AmpliTaq Gold (Perkin Elmer, Weiterstadt, Germany), 10nM of
each dNTP (dATP, dTTP, dCTP, and dGTP), and 1.67mM MgCl2.
After 35 PCR cycles, products were separated on 1.5% agarose gels,
stained with ethidium bromide, visualised with ultraviolet
light, recorded using a CCD camera, and assessed for expected
size. Quality of cDNA was tested by reverse-transcription PCR
(RT–PCR) using primers for housekeeping gene GAPDH. All
RT–PCR experiments were performed at least twice. Negative
controls without cDNA were integrated into all PCR reactions. To
assess primer specificity, PCR products were analysed repeatedly
by sequence analysis.
Real-time PCR
Primer sequences for target genes used in real-time are the same as
the ones used in conventional PCR. A master mix of the following
components was prepared at the indicated final concentrations:
4.0mM MgCl2, 400nM forward and reverse primers, 200nM dNTP
(Invitrogen, Karlsruhe, Germany), 1% DMF, BSA at 250mgml
 1,
SYBR Green I (Sigma, St Louis, MO, USA) diluted at 1:20000, and
1 Unit FastStart Taq DNA Polymerase (Roche Diagnostics,
Branchburg, NJ, USA) in a total volume of 20ml. Next, samples
were analysed using a LightCycler (Roche Diagnostics). After an
initial denaturation at 951C for 10min, PCR reactions were cycled
40 times as follows: 10s at 951C, 5s at adequate annealing
temperature (CXCL13 and CXCR5 at 611C; GADPH at 611C) and
15s at 721C (elongation). Fluorescence intensity was measured at
the end of each elongation phase. A melting curve analysis was
carried out immediately after amplification. A standard curve
prepared of the PCR product cloned into a pcDNA2.1 vector using
the TA cloning kit (Invitrogen, Karlsruhe, Germany) was prepared
to determine the concentration of target transcripts in cDNA
samples. Results are given as copy numbers of the target gene/
1 10
6 copies of housekeeping gene GAPDH.
Real-time PCR array
A quantitative mRNA expression analysis of 84 chemokines/
cytokines and their receptors was performed on 10 tumour tissue
samples and 10 healthy breast tissue samples applying the
chemokines/chemokine receptors RT2 profilert PCR Array
(SuperArray, Frederick, MD). The following chemokine and
related genes were analysed: chemokines: CCL1, CCL2, CCL3,
CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL17,
CCL18, CCL19, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8,
CXCL9, CXCL10, CXCL11, CXCL12, and CXCL13; chemokine
receptors: CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8,
CCR10, CCRL1, CCRL2, BLR1, CXCR3, CXCR4, CXCR6, and
CYFIP2; other chemokines and related genes: AGTRL1, BDNF, C5,
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sC5R1 (GPR77), CCBP2, CKLF, CKLFSF1, CKLFSF2, CKLFSF3,
CKLFSF4, CMKLR1, CSF3, CX3CL1, CX3CR1, ECGF1, GDF5,
GPR31, GPR77, GPR81, HIF1A, IL-13, IL-16, IL-18, IL-1A, IL-4,
IL-8RA, LTB4R, MMP2, MMP7, MYD88, NFKB1, SCYE1, SDF2,
SLIT2, TCP10, TLR2, TLR4, TNF, TNFRSF1A, TNFSF14, TREM1,
VHL, XCL1, and XCR1. Extraction of RNA and reverse transcrip-
tion were preformed as described above. PCR array analysis was
performed according to the manufacturer’s instructions using an
iCycler System (Bio-Rad, Waltham, MA, USA). RNA expression of
target genes was normalised for the expression of housekeeping
gene 18S rRNA, and results were compared between malignant and
normal samples according to the 2
 DDCt method. Results were
considered significant if tumour-related relative mRNA expression
was at least threefold higher or lower than that of autologous
healthy tissue.
Western blotting
Protein lysates were prepared from tumour samples, healthy breast
tissues, cell lines, and non-malignant tonsils using standard lysis
buffer containing a protease inhibitor cocktail (Sigma-Aldrich,
St Louis, MO, USA) and were subsequently denaturated for 10min
at 701C. Samples of lysates containing 30mg of total protein
were resolved on 4–12% Bis-Tris SDS–PAGE gels (Invitrogen,
Carlsbad, CA, USA) under reducing conditions. Proteins were
blotted on Hybond-ECL nitrocellulose membranes (Amersham
Biosciences, Piscataway, NJ, USA), blocked overnight at 41C with
Top-Block (Fluka, Buchs, Switzerland), and incubated with 1mgo f
primary antibody directed against CXCL13 (clone 53610; R&D
Systems), CXCR5 (clone 51505; R&D Systems), and b-actin (clone
SC-47778; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 4h
at room temperature. Next, secondary HRP-labeled anti-mouse
monoclonal antibody (R&D Systems) was applied for 1h at room
temperature. Specific binding was visualised by chemilumine-
scence (ECL Western Blotting Analysis System, Amersham
Biosciences).
Flow cytometry
For the analysis of CXCR5 protein expression, cell lines were fixed
using FACS Lysing Solution (BD Bioscience) and were permeabi-
lised using Permeabilising Solution (BD Bioscience). For analysis
of cell surface expression, cells were stained and then fixed; for
cytoplasmatic staining, cells were fixed and permeabilised before
staining with a PE-conjugated anti-CXCR5 antibody (Clone 51505,
R&D Systems) or an appropriate isotype control. Samples were
analysed using an FACSCalibur cytometer and CELLQuest soft-
ware (BD Biosciences).
Immunohistochemistry
Immunohistochemistry for CXCL13 and CXCR5 was performed on
formalin-fixed, paraffin-embedded tissue sections, which had been
obtained for routine diagnostics. Briefly, slides were deparaffinised
and pretreated with 10mmoll
 1 citrate, pH 6.0 (Zymed, South San
Francisco, CA, USA) in a steam pressure cooker (Decloaking
Chamber; BioCare Medical, Walnut Creek, CA, USA) followed by
washing in distiled water. All further steps were performed at room
temperature in a hydrated chamber. The slides were pretreated
with peroxidase block (Dako, Glostrup, Denmark), followed by
blocking with goat serum diluted at 1:5 in 50mmoll
 1 Tris-HCl,
pH 7.4 for 20min. Primary murine anti-human CXCL13 (clone
53610) and CXCR5 (clone 51505; both R&D Systems) antibodies
were applied at a 1:10 dilution in 50mmoll
 1 Tris-HCl, pH 7.4
with 3% goat serum for 1h. The slides were washed in 50mmoll
 1
Tris-HCl, and goat anti-mouse horseradish peroxidase-conjugated
antibody (Envision detection kit; Dako) was applied for 30min.
After further washing, immunoperoxidase staining was performed
using a Diaminobenzidine Chromogen Kit (Dako), as per the
manufacturer’s instructions, and the slides were counterstained
with haematoxylin.
Enzyme-linked immunosorbent assay
Serum concentrations of soluble CXCL13 protein were determined
using a commercially available Quantikine kit (R&D Systems)
according to the manufacturer’s instructions. After development of
the enzyme-linked immunosorbent assay (ELISA) plates, absor-
bance was read at 450nm using a spectrophotometer (SLT
Labinstruments, Salzburg, Austria). The concentration of CXCL13
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Figure 1 CXCL13 is the most strongly overexpressed chemokine in
breast cancer tissue as compared with normal breast tissue. Using a real-
time PCR-based and pathway-focused microarray analysis on tissue
samples from 10 patients whose tumours had been surgically removed,
we simultaneously analysed mRNA expression levels of 84 chemokines/
cytokines and their receptors in malignant and autologous healthy breast
tissue. All patients included were stratified according to their status of
disease (T2N0M0, stage II). (A) Dots represent mean expression of single
genes in malignant and healthy tissues after normalisation for housekeeping
gene 18S rRNA. Dotted lines indicate the arbitrary cutoff value of threefold
over- or underexpression in malignant vs normal tissues. (B) The
microarray analysis revealed 16 target genes that showed at least three
times higher or lower mRNA expression levels in malignant than in
autologous healthy breast tissue. Black columns represent genes upregu-
lated in tumours and white columns indicate genes that were down-
regulated as compared with normal breast tissue.
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sin the sera was interpolated from a standard curve, which was
generated using the respective recombinant protein.
Statistical analysis
The Wilcoxon test was applied to results from tumour samples vs
autologous healthy tissues, whereas the Mann–Whitney U-test was
used to examine differences between samples of tumour patients
and controls. Spearson’s rank test was used to analyse correlations
between gene expression and clinicopathological characteristics of
the patients. Statistical analysis was performed using SPSS software
(SPSS Inc., Chicago, IL, USA). Results were considered significant
with Po0.05.
RESULTS
Microarray analysis demonstrates strong CXCL13
overexpression in breast cancer tissue as compared with
normal breast tissue
Given the increasingly important role of chemokine/chemokine
receptor interactions in the development and spreading of various
malignancies, we aimed at applying a screening approach to look
for chemokines that might have significant functions in the
biology, and possibly in the pathophysiology, of breast cancer. We
therefore performed a real-time PCR-based and pathway-focused
microarray analysis on malignant and autologous healthy breast
tissue samples from 10 patients whose tumours had been surgically
removed. All patients included showed the same status of disease
(T2N0M0; stage II). Simultaneously examining mRNA expression
levels of 84 chemokines/cytokines and their receptors in malignant
and non-malignant tissue, we found 16 target genes that were
differently expressed in breast cancer tissues as compared with
their normal counterparts (Figure 1A and B). Six genes were
significantly higher expressed in tumour tissue than in healthy
tissue. Of these, chemokine CXCL13 was by far the most strongly
and consistently overexpressed gene with a mean expression level
in tumour samples that was 18 times higher than the one observed
in autologous benign breast samples (Figure 1B).
CXCL13 is consistently overexpressed at the RNA and
protein levels in tumour samples of breast cancer patients
To confirm our findings obtained by the RT–PCR array, we
applied a CXCL13-specific real-time PCR to a larger set of samples
from 34 breast cancer patients comprising all stages of disease
(Table 1). Performing a comparative analysis of malignant and
autologous healthy breast tissues, we observed readily detectable
levels of CXCL13 in malignant as well as in non-malignant samples
(Figure 2A). Comparing CXCL13 mRNA expression levels of
malignant and normal breast tissue samples, however, we found
that CXCL13 mRNA levels were significantly elevated in the
malignant samples, confirming that increased expression of this
chemokine is indeed a feature distinguishing tumour-infiltrated
breast tissues from their healthy counterparts. Examining the
presence of CXCR5, which is the only known receptor for
chemokine CXCL13, within breast cancer tissues, we detected
only a comparably weak expression (Figure 2A). We also did not
observe any significant correlations between tumour RNA expres-
sion of CXCL13 or CXCR5 and clinical characteristics of individual
patients (data not shown). However, we detected a strong and
significant (P¼0.0004) correlation between copy numbers of both
genes analysed within breast cancer tissue (Figure 2B), indicating a
biologically relevant role of CXCR5 as a receptor for CXCL13 in
this solid tumour.
Performing Western blot analyses of CXCL13 and CXCR5
expressions on lysates of six randomly selected breast cancer
samples and four healthy breast tissue samples, we observed a
weak but constantly detectable expression of the chemokine
receptor CXCR5 in tumour samples, whereas protein expression of
this chemokine receptor was not detectable in the healthy samples
analysed (Figure 2C). In accordance with RNA expression levels,
CXCL13 protein was commonly found in tumour samples, whereas
it was absent from all healthy breast tissues analysed (Figure 2C).
Marked overexpression of CXCL13 protein in breast cancer tissue
was further confirmed performing a quantitative ELISA analysis
with the same lysates of tumours and healthy controls. Remark-
ably, in this quantitative assay, protein concentrations of CXCL13
in breast cancer samples almost approached the levels found in
non-malignant inflamed tonsils, which served as a positive control
(Figure 2D).
CXCL13 and CXCR5 are expressed intracellularly in breast
cancer cell lines but are not detectable on the cell surface
Given the significant overexpression of CXCL13 at the mRNA and
protein levels in breast cancer tumour samples, we sought to
determine the expression patterns of the chemokine ligand and its
receptor in human breast cancer cell lines. We analysed six
different breast cancer cell lines and found RNA and protein
expressions of CXCL13 in all but one and CXCR5 expression in
four of six cell lines (Figure 3A). Analysing the breast cancer lines
by flow cytometry, we failed to detect a significant surface
expression of the chemokine receptor, however, by performing
intracellular staining, we observed strong expression of CXCR5 in
the cytoplasma of cell lines ZR-75, BT-20, and MCF-7 (Figure 3B).
Technical difficulties, mainly due to unspecific intracellular
staining, did not allow for accurate analysis of CXCL13 expression
Table 1 Clinicopathological characteristics of breast cancer patients
analysed for CXCL13/CXCR5 expression by real-time PCR
Characteristics Number of patients per group
Total 34
Age (median and range) years 63 (43–85)
pT status
pT1 13
pT2 19
pT3 0
pT4 1
pN status
pN0 20
pN1 9
pN2 3
pN3 2
M status
M0 30
M1 2
Stage
I1 0
II 15
III 4
IV 2
Grading
Well differentiated 4
Moderately differentiated 21
Poorly differentiated 8
A total of 34 patients with breast cancer were classified according to clinical features
and pathological characteristics of their tumour samples. Assessment of T status and
grading was only available for 33 patients, M status and classification into stages of the
disease for 32 and 31 patients, respectively.
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sby flow cytometry (data not shown). Therefore, we performed
extensive analyses of CXCL13 protein concentrations in the
supernatant of breast cancer cell lines that had been cultured for
72h under different conditions to find shed CXCL13. However,
culturing of cell lines with or without the addition of activating
cytokine TNF-a or INF-g did not result in the detection of CXCL13
in the supernatant (Figure 3C), whereas intracellular CXCL13
mRNA was consistently detectable using real-time PCR, indepen-
dently from the addition of cytokines. Accordingly, CXCR5 mRNA
was consistently detectable using real-time PCR, but the tumour
cells remained negative for surface expression of the protein even
after the addition of activating cytokines (Figure 3C).
Epithelial tumour cells of patients with breast cancer show
immunohistochemically detectable overexpression of
CXCL13
To further validate our findings of CXCL13 protein overexpression
in human breast cancer and to localise the expression within a
given tissue sample, we performed immunohistochemistry on
breast cancer samples and autologous breast tissue samples of
the same patients using lymph follicles as positive controls.
Importantly, we did not observe significant numbers of tumour-
infiltrating leukocytes expressing CXCL13 or CXCR5. However, we
found a strong cytoplasmatic expression of CXCL13 in epithelial
tumour cells, which was comparable with levels found in lymph
follicles of draining lymph nodes from the same patients
determined to be free of tumour (Figure 4). Benign epithelial cells
also expressed CXCL13, however, to a much lesser extent. CXCR5
staining of the same specimens revealed a weak cytoplasmatic
staining of epithelial cells with comparable levels between
malignant and benign samples.
Levels of CXCL13 protein are increased in the serum of
breast cancer patients
Breast cancer cell lines might not reflect the biological behaviour of
original tumour tells and certain features, such as chemokines
secretion or release might diminish or wear off during cell culture
and repeated passages. Therefore, we next asked the question
whether soluble CXCL13 protein could be detected in the in vivo
setting, given the high levels of protein expression within breast
cancer tissue samples as shown above. To this end, we analysed
serum concentrations of CXCL13 protein in 44 healthy blood
donors, 48 breast cancer patients without evidence of disease after
surgical resection of their tumour, and 54 patients with metastatic
breast cancer. Although there was no difference in CXCL13 serum
concentrations between the healthy control group and patients
without evidence of disease (Figure 5), we found significantly
elevated serum concentrations of CXCL13 in patients with
metastatic disease as compared with normal controls and with
breast cancer patients without evidence of disease after surgical
removal of their original tumour.
DISCUSSION
Besides our current report, there are very limited data on CXCL13
or CXCR5 expression in non-migratory cells, let alone in solid
tumours. In one report, immunohistochemistry revealed CXCR5
expression in a significant proportion of human colon carcinoma
specimens (Gunther et al, 2005), whereas another group demon-
strated cytoplasmatic expression in pancreatic cancer cells and cell
lines (Meijer et al, 2006). We show here for the first time that the
ligand for CXCR5, CXCL13, is the most significantly overexpressed
chemokine in breast cancer, supporting the idea of a role of
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Figure 2 CXCL13 is consistently overexpressed in tumours of breast cancer patients. (A) Tumours and non-malignant breast tissues of 34 patients with
breast cancer were analysed regarding the expression levels of CXCL13 and its receptor CXCR5 applying real-time PCR and results were normalised to the
expression levels of housekeeping gene GAPDH. Black dots represent copy numbers of the target gene for each benign or malignant sample, respectively,
and bars represent medians calculated. Benign and malignant samples were compared using Wilcoxon’s test. (B) Performing a correlative analysis of
CXCL13 and CXCR5 RNA expressions in breast cancer samples, a significant association between expression levels of both genes was observed. (C)
Lysates of six tumour samples, four healthy breast tissues, and one non-malignant tonsil were analysed by Western blot for the protein expressions of
CXCL13 and CXCR5. (D) To confirm findings obtained in the Western blot analysis, an ELISA was performed quantifying the absolute concentration of
CXCL13 protein in lysates consisting of whole breast cancer protein.
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progression of this tumour type and, possibly, other human
cancers. Furthermore, given the elevated CXCL13 expression in the
serum of patients with metastatic disease as compared with
patients without evidence of tumour burden, this chemokine may
also serve as a tumour marker.
In our analysis of breast cancer cell lines and tumour samples,
we found the expression of chemokine receptor CXCR5 to be
restricted to the cytoplasma, a finding that is in line with
observations of Muller et al (2006) who detected CXCR5
intracellulary but did not detect surface expression of CXCR5 in
cell lines and tumour samples from patients with metastatic head
and neck cancer. Although these findings, at first glance, do not
support the concept of CXCR5 as the main target for CXCL13
overexpression in breast cancer, we believe that they do not reflect
the potential role this chemokine receptor might play in vivo.I t
may very well be that tumour cells express surface CXCR5 only
during certain stages of tumour organisation and internalise the
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Figure 3 CXCL13 and its receptor CXCR5 are expressed intracellularly in breast cancer cell lines. (A) Expressions of chemokine CXCL13 and its
receptor CXCR5 were examined in six breast cancer cell lines applying conventional RT–PCR (upper rows) and Western blot (lower rows). Housekeeping
genes GAPDH and b-actin served as internal controls. (B) Breast cancer cell lines ZR-75, BT-10, and MCF-7 were examined regarding the protein
expression of CXCR5 using flow cytometry. Histograms indicate staining intensity applying anti-CXCR5 antibody (black) or an appropriate isotype control
(grey). (C) Seven breast cancer cell lines were cultured for 72h in complete medium with or without activating cytokine TNF-a or INF-g. mRNA levels of
CXCL13 and CXCR5 were evaluated at baseline as well as after 24, 48, and 72h applying real-time PCR. At the same time points, the concentration of
CXCL13 protein in the culture supernatant was quantified using an ELISA. Cell surface expression of CXCR5 protein was evaluated by flow cytometry.
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of ligand CXCL13. This idea is supported by the findings of
others who observed that, in the case of chronic lymphatic
leukaemia, CXCR5 and its ligand were overexpressed in malignant
B cells but that CXCR5 was downregulated after stimulation
with soluble CXCL13 (Burkle et al, 2007). Importantly, a concen-
tration gradient- and time-dependent downregulation would also
explain our observation of a strong correlation between CXCL13
expression and the presence of its receptor within breast cancer
tissues despite the lack of CXCR5 overexpression in the same
tissues.
In addition, the hypothesis that an externalisation of receptor
CXCR5 is restricted to certain phases of cancer development
in vivo is also supported by the findings of Meijer et al (2006) who
did not detect CXCR5 expression on a variety of tumour cell lines
cultured in vitro but who found this chemokine receptor to be
expressed on the surface of the same cells several days after
injection into mice.
What might the biological role of CXCR5/CXCL13 interactions
be in the case of human cancers? Our finding of increased levels of
soluble CXCL13 protein in the peripheral blood of breast cancer
patients with advanced disease clearly suggests that this chemo-
kine might be involved in the process of metastasisation. One
might imagine at least three possible ways for CXCL13 to mediate a
promoting effect on tumour development, the first two of them
involving cellular immunity. First, it could be that breast cancer
cells produce and release chemokines to allure cells, such as
lymphocytes, monocytes, or dendritic cells, that are capable of
secretion of cytokines directly promoting tumour cell growth and
survival. Such an effect has been demonstrated for Hodgkin’s
lymphoma (Teruya-Feldstein et al, 1999; Buri et al, 2001). Another
possibility might be that CXCL13 mediates some form of
protection against immune-mediated anti-tumour immunity. Such
a phenomenon has been reported for leukaemias, where CXCL13-
expressing malignant B cells showed an increased resistance
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Normal
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0.4 mm
Figure 4 Immunohistochemistry localises the overexpression of CXCL13 to epithelial tumour cells in tissue samples of breast cancer patients.
Immunohistochemical staining using appropriate anti-CXCL13 and anti-CXCR5 antibodies was performed on 10 paraffin-embedded malignant or non-
malignant tissue samples, respectively. Non-malignant lymph follicles removed from breast tissue served as a positive control for CXCL13 and CXCR5
stainings and showed homogenous staining throughout the node.
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Figure 5 Serum concentrations of CXCL13 are elevated in breast
cancer patients with metastatic disease. Serum concentrations of CXCL13
were analysed by ELISA in 44 healthy blood donors (white bar), 48 breast
cancer patients without evidence of disease after surgical resection of their
tumour and 54 patients with metastatic breast cancer (black bars). Bars
show mean concentrations of CXCL13 plus standard deviations. Results
were compared between groups applying the Mann–Whitney U-test.
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sagainst TNF-a-mediated apoptosis (Qiuping et al, 2005; Chunsong
et al, 2006).
Our observation of a very low frequency of CXCL13-expressing
leukocytes present within breast cancer tissue, however, would
argue against the latter two hypotheses. Therefore, we favour the
third possible explanation, suggesting that breast cancers cells
might supply themselves with a growth advantage by the
expression of CXCR5 and the release of CXCL13 in vivo. This
view is also supported by a recent study demonstrating a growth
advantage of CXCR5-positive cancer cells within the liver of mice
presumably through CXCL13 produced by liver cells in their
microenvironment (Meijer et al, 2006).
In our view, the most perspicuous explanation for the increased
presence of CXCL13 in breast cancer is that CXCR5/CXCL13
interactions might function in a similar way as they do in
lymphatic tissue. Breast cancer cells might interact through
CXCR5/CXCL13 interactions to organise cellular cluster formation
and compartmentalisation as has been shown for B cells in renal
allografts (Steinmetz et al, 2005) and in salivary glands of patients
with Sjogren’s syndrome (Barone et al, 2005). This way, CXCL13
and its ligand might contribute significantly to tumour formation,
and therapeutic interventions aiming at interrupting CXCL13/
CXCR5 interactions might be of benefit for the clinical course of
patients with breast cancer.
It has recently been shown (Burkle et al, 2007) that the
stimulation of leukaemic B cells with CXCL13 results in a
prolonged activation of p44/42 mitogen-activated protein kinases.
Interestingly, p44/42 mitogen-activated protein kinase activation
has also been shown to be involved in oncogenic transformation of
epithelial breast cancer cells and their protection from oxidative
stress (Zhu et al, 2005; Mohankumar et al, 2007). Therefore, we
suggest that this kinase pathway represents one possible route
through which CXCL13/CXCR5 interactions might exert their
biological function on a molecular level. Unfortunately, the lack of
CXCR5 surface expression on breast cancer cell lines did not allow
for consequent functional analyses of the role of CXCL13 in breast
cancer in vitro. Further studies, however, are underway in our
laboratory examining the exact consequences of CXCL13/CXCR5
interactions for the development and/or progression of breast
cancer in vivo.
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